Vivek V Bhosale1, S C Inamdar2, Karande V B3, Burute S R3, Murthy M B3, Ghatak A4. 1. Scientist, Clinical and Experimental Medicine, CSIR-Central Drug Research Institute , Lucknow, India . 2. Associate Professor, Department of Pharmacology, Government Medical College , Miraj, Maharashtra, India . 3. Lecturer, Department of Pharmacology, Government Medical College , Miraj, Maharashtra, India . 4. Chief Scientist, Clinical and Experimental Meidcine, CSIR-Central Drug Research Institute , Lucknow, India .
Abstract
INTRODUCTION: Hypertension, "The silent killer" is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third generation beta blocker with additional vasodilating property due to nitric oxide release. AIM: The current study aims to assess efficacy and safety of Nebivolol and compare with Atenolol. METHODS: This was prospective, double blind, comparative controlled clinical study. Total 90 patients were enrolled into study as per selection criteria. Patients were randomized to receive Atenolol and Nebivolol with 45 patients in each group for 12 weeks. RESULTS AND CONCLUSION: The mean reduction diastolic blood pressure in Nebivolol and Atenolol group was 10.77±2.60 and 10.05±2.83 respectively. The number of patients with adverse effect events was higher in the Atenolol than in the Nebivolol group (36.84% of Atenolol Vs 12.82% of Nebivolol). Thus it can be concluded that, for the same antihypertensive effect, Nebivolol was better tolerated than Atenolol.
RCT Entities:
INTRODUCTION:Hypertension, "The silent killer" is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third generation beta blocker with additional vasodilating property due to nitric oxide release. AIM: The current study aims to assess efficacy and safety of Nebivolol and compare with Atenolol. METHODS: This was prospective, double blind, comparative controlled clinical study. Total 90 patients were enrolled into study as per selection criteria. Patients were randomized to receive Atenolol and Nebivolol with 45 patients in each group for 12 weeks. RESULTS AND CONCLUSION: The mean reduction diastolic blood pressure in Nebivolol and Atenolol group was 10.77±2.60 and 10.05±2.83 respectively. The number of patients with adverse effect events was higher in the Atenolol than in the Nebivolol group (36.84% of Atenolol Vs 12.82% of Nebivolol). Thus it can be concluded that, for the same antihypertensive effect, Nebivolol was better tolerated than Atenolol.
Authors: Y Pesant; J Marc-Aurèle; P Bielmann; P Alaupovic; P Cartier; D Bichet; G Thibault; P J Lupien Journal: Am J Ther Date: 1999-05 Impact factor: 2.688
Authors: R Fogari; A Zoppi; P Lazzari; A Mugellini; P Lusardi; P Preti; L Van Nueten; C Vertommen Journal: J Hum Hypertens Date: 1997-11 Impact factor: 3.012
Authors: L M Van Bortel; J G Breed; J Joosten; J A Kragten; F A Lustermans; J M Mooij Journal: J Cardiovasc Pharmacol Date: 1993-06 Impact factor: 3.105
Authors: Otto Kamp; Marco Metra; Silvia Bugatti; Luca Bettari; Alessandra Dei Cas; Natalia Petrini; Livio Dei Cas Journal: Drugs Date: 2010 Impact factor: 9.546